Loading…
ORIC Pharmaceuticals, Inc. is projected to rise to $13.28 by 2027, a +20% move from its current price of $11.07. ORIC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $10.69 | $11.07 | $11.47 | +0.03% |
| Aug 3 | $10.53 | $11.08 | $11.64 | +0.05% |
| Aug 4 | $10.42 | $11.08 | $11.78 | +0.08% |
| Aug 5 | $10.32 | $11.08 | $11.89 | +0.10% |
| Aug 6 | $10.24 | $11.08 | $12.00 | +0.13% |
| Aug 7 | $10.17 | $11.09 | $12.09 | +0.15% |
| Aug 8 | $10.10 | $11.09 | $12.18 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.10 | $11.09 | $12.18 | +0.18% |
| Week 2 | $9.73 | $11.11 | $12.68 | +0.36% |
| Week 3 | $9.46 | $11.13 | $13.09 | +0.53% |
| Week 4 | $9.24 | $11.15 | $13.45 | +0.71% |
| Week 5 | $9.06 | $11.17 | $13.77 | +0.89% |
| Week 6 | $8.89 | $11.19 | $14.08 | +1.07% |
| Week 7 | $8.75 | $11.21 | $14.36 | +1.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of therapies to counter resistance mechanisms in cancers in the United States.
Its clinical stage product candidates include enozertinib, formerly ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, that selectively targets epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat, formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.
The company has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
ORIC Pharmaceuticals, Inc. (ORIC) operates in the Healthcare sector as a clinical-stage biotech company focused on cancer resistance mechanisms. The stock trades at $11.07 per share with a market capitalization of $1.15B and a market rank of 2339.
Technically, the stock shows a BULLISH sentiment with an RSI14 of 50. It trades vs. the SMA50 of $9.66 and the SMA200 of $10.58, with a defined support at $8.49 and a resistance at $12.10.
The 30-day price range runs from $8.76 to $13.98, reflecting recent volatility within a defined band. The forecast indicates an upside trajectory over multiple years, with 2026 averaging $11.07 and rising to substantial gains by later years (e.g., 2030 avg $24.17; 2040 avg $67.22; 2050 avg $162.09), and ROIs expanding from 0% in 2026 to 1364.3% in 2050.
A major floor 37.3% below — a decisive break under it would weaken the trend.
The nearest floor, 23.3% below — buyers have tended to step in here.
The nearest ceiling, 9.3% above — a clean break opens room to run.
A major ceiling 27.9% above — clearing it would confirm fresh momentum.
Key ORIC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ORIC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.58 | Sell | $11.39 | Sell |
| MA 10 | $11.29 | Sell | $11.31 | Sell |
| MA 20 | $11.05 | Buy | $10.97 | Buy |
| MA 50 | $9.66 | Buy | $10.29 | Buy |
| MA 100 | $9.95 | Buy | $10.15 | Buy |
| MA 200 | $10.58 | Buy | $10.17 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.72 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 3.50 | Neutral |
| Williams %R (14) | -61.31 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -0.63 | Sell |
| Bollinger %B (20,2) | 0.51 | Neutral |
| Stochastic %K (14) | 38.69 | Neutral |
| TRIX (15) | 0.79 | Buy |
| Awesome (5,34) | 1.21 | Buy |
| Ultimate (7,14,28) | 56.39 | Neutral |
| Momentum (10) | 0.34 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 11.52 | Sell |
| ADX (14) | 23.18 | Buy |
| ATR (14) | 0.34 | Info |
The near-term technical picture shows bullish momentum with a neutral RSI around 50. The stock trades above the 50-day average at $9.66 and above the 200-day average at $10.58, framing a constructive medium-term path.
Investors can note the defined support at $8.49 and resistance at $12.10, suggesting a tradeable range within the 30-day window. The 30-day range spans from $8.76 to $13.98, indicating volatility but with a clear upper and lower boundary to guide near-term decisions.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.47 | $11.07 | $14.59 | 0% | Neutral | |
| $10.30 | $13.28 | $18.26 | +20% | Neutral | |
| $10.51 | $14.06 | $20.26 | +27% | Bullish | |
| $13.78 | $19.03 | $28.43 | +72% | Bullish | |
| $17.01 | $24.17 | $37.20 | +118% | Bullish | |
| $19.08 | $27.81 | $43.94 | +151% | Bullish | |
| $21.86 | $32.62 | $52.77 | +195% | Bullish | |
| $20.77 | $31.71 | $52.38 | +186% | Bullish | |
| $21.61 | $33.72 | $56.78 | +205% | Bullish | |
| $27.30 | $43.50 | $74.56 | +293% | Bullish | |
| $38.32 | $67.22 | $124.05 | +507% | Bullish | |
| $77.77 | $162.09 | $332.61 | +13.6x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $7.47 | $11.07 | $13.71 | +0.00% |
| September 2026 | $9.74 | $11.63 | $14.35 | +5.05% |
| October 2026 | $9.41 | $11.33 | $14.17 | -2.58% |
| November 2026 | $9.12 | $11.06 | $13.98 | -2.38% |
| December 2026 | $9.36 | $11.43 | $14.59 | +3.35% |
Click any year to see its month-by-month ORIC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
ORIC Pharmaceuticals, Inc.'s 2026 outlook centres on $11.07, within a $7.47 to $14.59 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ORIC could reach as high as $18.26, with a base case around $13.28 and support toward $10.30 — roughly +20% from $11.07. A consolidation phase looks the most probable path here.
Expect ORIC to range from $10.51 to $20.26 through 2028. The $14.06 average target implies a +27% move from current prices. That is up +6% on the projected 2027 average. Momentum favours further upside here.
The ORIC price prediction for 2029 points to an average of $19.03 (low $13.78, high $28.43) — a potential gain of +72% on today's $11.07. Buyers look set to stay in control over this stretch.
In 2030, ORIC is projected to trade between $17.01 and $37.20, averaging $24.17 — a potential gain of +118% from today's $11.07. That is up +27% on the projected 2029 average. Momentum favours further upside here.
ORIC Pharmaceuticals, Inc.'s 2031 outlook centres on $27.81, within a $19.08 to $43.94 range. That is up +15% on the projected 2030 average. That marks a +151% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ORIC could reach as high as $52.77, with a base case around $32.62 and support toward $21.86 — roughly +195% from $11.07. Momentum favours further upside here.
Expect ORIC to range from $20.77 to $52.38 through 2033. The $31.71 average target implies a +186% move from current prices. That is -3% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The ORIC price prediction for 2034 points to an average of $33.72 (low $21.61, high $56.78) — a potential gain of +205% on today's $11.07. Momentum favours further upside here.
In 2035, ORIC is projected to trade between $27.30 and $74.56, averaging $43.50 — a potential gain of +293% from today's $11.07. That is up +29% on the projected 2034 average. Buyers look set to stay in control over this stretch.
ORIC Pharmaceuticals, Inc.'s 2040 outlook centres on $67.22, within a $38.32 to $124.05 range. That is up +55% on the projected 2035 average. That marks a +507% change versus current levels. Momentum favours further upside here.
By 2050, ORIC could reach as high as $332.61, with a base case around $162.09 and support toward $77.77 — roughly +13.6x from $11.07. Buyers look set to stay in control over this stretch.
Investing $1,000 in ORIC today (≈ 90.334237 ORIC) could be worth
$14,642.69
+$13,642.69 (+1364%) by 2050 · US Dollar
Based on the average projected ORIC price of $162.09 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ORICwould be worth at today's price.
$1,000 invested in ORIC on Jul 31, 2025 (≈ 100.3009 ORIC) would be worth
$1,110.33
+$110.33 (+11.0%) today · 1.11× · US Dollar
Based on a ORIC entry price of $9.97 vs. today's $11.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $12.1 | $914.88 | -8.5% |
| 1 month ago | $10.89 | $1,016.53 | +1.7% |
| 3 months ago | $9.77 | $1,133.06 | +13.3% |
| 6 months ago | $11.16 | $991.94 | -0.8% |
| 1 year ago | $9.97 | $1,110.33 | +11.0% |
| All time (5.0y) ago | $16.61 | $666.47 | -33.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ORIC forecast.
Our base-case forecast reaches $22.00 around 2030.
Implied market cap at $22.00: $2.28B
The multi-year forecast paints a bullish trajectory across the latter part of the decade and into the 2030s and beyond. The 2026 forecast sits at an avg of $11.07 with a min of $7.47 and a max of $14.59, yielding 0% ROI and a neutral sentiment.
By 2030, the avg rises to $24.17 with a min of $17.01, a max of $37.20 and an ROI of 118.3%, reflected in a bullish outlook.
Looking further, 2040 shows an avg of $67.22, a min of $38.32, a max of $124.05 and an ROI of 507.2%, maintaining a bullish stance. By 2050, the avg is $162.09 with a min of $77.77 and a max of $332.61, and an ROI of 1364.3%, again with bullish sentiment.
These figures illustrate a substantial expansion in expected value over time, but they are estimates, not guarantees, and depend on a range of factors that can influence performance.
Tap a question to reveal the answer.
2030 avg $24.17; min $17.01; max $37.20; ROI 118.3%; sentiment bullish.
The forecast shows rising averages and ROIs across years, with 2040 avg $67.22 (ROI 507.2) and 2050 avg $162.09 (ROI 1364.3), but these are estimates and not guarantees.
Yes, the forecast max reaches $124.05 in 2040 and $332.61 in 2050, indicating potential to exceed $100 under certain scenarios; these are not guarantees.
Sentiment is bullish, RSI14 is 50, 30-day range is $8.76 to $13.98, with support at $8.49 and resistance at $12.10. The SMA50 is $9.66 and the SMA200 is $10.58.
Current price is $11.07 and market cap is $1.15B.
ORIC Pharmaceuticals, Inc. Community Discussion
0Share your ORIC Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.